Prolonged molecular remission in PML-RARα-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate [4]

Leukemia

Volumn 19, Issue 9, 2005, Pages 1676-1677

  McMullin, M F ^a   Nugent, E ^b   Thompson, A ^a   Hull, D ^c   Jones, F G C ^a   Grimwade, David ^b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; HISTONE DEACETYLASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; PHENYLBUTAZONE; PHENYTOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; VALPROIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR PROTEIN;

ADULT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DRUG BLOOD LEVEL; EPILEPTIC STATE; FEMALE; GENE MUTATION; GINGIVA BLEEDING; HUMAN; LETTER; LEUKEMIA REMISSION; MAINTENANCE THERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SKIN BRUISING; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; GENETICS; METABOLISM; REMISSION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; TREATMENT OUTCOME; VALPROIC ACID;

EID: 26944443973     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403883     Document Type: Letter

References (8)

1. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: Implications for the clinical management of the disease. Blood Rev 2003; 17: 71-97.
2. He L-Z, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321-1330.
3. Kitamura K, Hoshi S, Koike M, Kiyoi H, Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 2000; 108: 696-702.
4. Warrell Jr RP, He L-Z, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-1625.
5. Göttlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978.
6. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
7. Zhou D-C, Kim SH, Ding W, Schultz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
8. Diverio D, Rossi V, Avvisati G, De Santis S, Pustilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptive-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998; 92: 784-789.